Specialized Therapies | HIV and Oncology
Press Releases and Company Announcements
Theratechnologies to Present Preliminary Safety and Efficacy Data from Phase 1 Trial of Sudocetaxel Zendusortide in Heavily Pretreated Cancer Patients at ASCO 2023
Theratechnologies’ Trogarzo® (Ibalizumab-uiyk) Shortens Time to HIV Undetectability and Extends Durability of Undetectability and Viral Suppression in a Matched Treatment Comparison
Theratechnologies Data Presentations at AACR 2023 Showcase Potential of Sudocetaxel Zendusortide as a Single Agent and in Combination with other Anticancer Therapies
Pipeline & Medicines
Product Pipeline & Portfolio
Theratechnologies develops and commercializes innovative therapies. The Company currently commercializes two products in the field of HIV. Trogarzo® and EGRIFTA SV® are approved in the United States. We have a Phase 1 clinical trial in oncology using our novel and proprietary SORT1+ Technology™. We also plan to initiate a Phase 3 clinical trial to evaluate tesamorelin as a potential treatment for nonalcoholic steatohepatitis (NASH), a severe liver condition which affects a growing number of people around the world.
Our Commercialized Products
Making a difference through innovation
Theratechnologies makes a difference in the lives of patients through the development and commercialization of products addressing important unmet medical needs.